
David H. Sherr, PhD,
Professor, Pathology and Laboratory Medicine, Boston University

Rakesh Dixit, PhD, DABT,
President & CEO, Bionavigen

Roy Baynes, MD, PhD,
Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

Mark C. Poznansky, MD, PhD,
Director, Vaccine & Immunotherapy Center, Massachusetts General Hospital; Associate Professor, Harvard Medical School

Jonathan Cheng, MD,
Vice President & Oncology Therapeutic Area Head, Merck

Bruno Gomes, DVM, PhD,
Global Head of Biomarkers Oncology, Roche

Jill Loftiss
Head, Clinical Operations & Oncology, MedImmune

Céline Adessi, PhD,
Senior Group Director, Product Development, Safety Science Oncology, Licensing and Early Development, F. Hoffmann-La Roche

George A. Green IV, PhD,
Executive Director, Precision Medicine, Head, Pharmacodiagnostics, Translational Medicine, Bristol-Myers Squibb

Michael Woo, PhD,
Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

Daniela Cipolletta, PhD,
Lab Head, Investigator III, Immuno-Oncology, Novartis Institutes for BioMedical Research

Elaine Pinheiro, PhD,
Senior Principal Scientist, Oncology, Merck